TIFA Polyclonal Antibody, PE-Cy5.5 Conjugated
Product Specifications
Background
Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.
Synonyms
Putative MAPK activating protein PM14; Putative MAPK-activating protein PM14; Putative NF kappa B activating protein 20; Putative NF-kappa-B-activating protein 20; T2BP; TA; TA_HUMAN; TRAF interacting protein with FHA domain containing protein A; TRAF-interacting protein with FHA domain-containing protein A; TRAF2 binding protein; TRAF2-binding protein.
Cellular Locus
Cytoplasm, Nucleus
Host
Rabbit
Cross Reactivity
Mouse
Immunogen
51-150/184
Target
TIFA
Clonality
Polyclonal
Isotype
IgG
Conjugation
PE-Cy5.5
Source
KLH conjugated synthetic peptide derived from human TIFA
Applications
WB
Purification
Purified by Protein A.
Excitation Emission
488nm/694nm
Concentration
1µg/µl
Dilution
WB (1:300-5000)
Buffer
Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Modification
Unmodified
Storage Conditions
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Predicted Cross Reactivity
Human, Rat, Dog, Cow, Sheep, Pig, Chicken
More Discoveries
Explore Other Products
Browse additional items from our catalog
LV695211 1.0 µg DNA
SNAPAP Lentiviral Vector (Rat) (CMV) (pLenti-GIII-CMV-GFP-2A-Puro)
Sign In for Pricing
View Details 
Z06591-500 500 µg
HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Tetramer, His & Avi, Human
Sign In for Pricing
View Details